Isatuximab plus carfilzomib-dexamethasone for relapsed multiple myeloma
Mené sur 302 patients atteints d'un myélome multiple réfractaire ou récidivant (durée médiane de suivi : 56,6 mois), cet essai multiple de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout d'isatuximab à un traitement combinant carfilzomib et dexaméthasone
In the past 15 years, considerable advances have been made in the number of therapies available for patients with multiple myeloma. 1 One type of agent available for this purpose is anti-CD38 monoclonal antibodies, including isatuximab and daratumumab. However, considering that patients with multiple myeloma usually experience multiple relapses, there is a continued need to develop effective treatment strategies (including novel combinations) for patients with relapsed or refractory multiple myeloma.